# Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Source: https://onco.cc/trials/nct01744223/  
OnCo record `nct01744223` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BPX-501 dose 1 in acute lymphoblastic leukaemia, non-Hodgkin lymphoma and myelodysplastic syndromes / neoplasms, run by Bellicum Pharmaceuticals, active and no longer recruiting.

## Summary

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant is a phase 1/2 interventional study registered as NCT01744223 by Bellicum Pharmaceuticals, with 36 participants enrolled, started 2013-03 and due to reach its primary completion in 2019-10-09. Interventions recorded: BPX-501 dose 1, Rimiducid, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4 and SCT.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01744223
- Phase: 1/2
- Setting: A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
- Sponsor: Bellicum Pharmaceuticals
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT01744223: https://clinicaltrials.gov/study/NCT01744223

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Bellicum Pharmaceuticals](https://onco.cc/companies/bellicum/)

---
JSON: https://onco.cc/api/v1/entities/nct01744223.json